Slide 1: Q2 2026 Earnings Presentation
Q2 2026 Earnings Presentation July 30, 2026 1
Slide 2: Forward-looking statements and non-GAAP information
Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; ou
Slide 3: Our vision is to transform cancer care for patients all over the world
Our vision is to transform cancer care for patients all over the world 3
Slide 4: Leveraging our platform across the cancer care continuum
Leveraging our platform across the cancer care continuum Risk Treatment Recurrence Diagnosis Prognosis Assessment Guidance Monitoring W O ME N ’ S H E A L TH Breast UROLOGY + UROLOGY UROLOGY With Decipher With Decipher Prostate Prostate Prostate UROLOGY UROLOGY TrueMRD MIBC Bladder ENDOCRINOLOGY Thy
Slide 5: Prognostic and predictive testing for breast cancer
Prognostic and predictive testing for breast cancer Provides additional data around the risk of recurrence and biological classification of the cancer to help inform treatment decisions Launched following the Prosigna is backed by the Represents one of the practice-changing most rigorous clinical mo
Slide 6: OPTIMA trial met its primary endpoint, delivering level 1A prospective evidence for the Prosigna test
OPTIMA trial met its primary endpoint, delivering level 1A prospective evidence for the Prosigna test More than two-thirds of clinically high-risk patients may safely avoid chemotherapy without compromising outcomes ~225,000 patients diagnosed annually in This includes premenopausal women and patien
Slide 7: Clinical evidence supporting the Prosigna test is extensive and growing
Clinical evidence supporting the Prosigna Legend: Ongoing test is extensive and growing In Analysis Published Prosigna Breast Publications 157 OPTIMA and growing Development Clinical Prognostic1 Clinical Predictive2 Real-World / Decision-Impact GEP Test Comparisons 1. Demonstrates that PAM50 or the
Slide 8: Exceptional engagement since launch from patients, clinicians, KOLs and the broader oncology community
Exceptional engagement since launch from patients, clinicians, KOLs and the broader oncology community Some of these organizations are evaluating Actively engaged with using Prosigna for all more than 100 institutions that help shape standards of care in early-stage HR+ breast breast cancer, with gr
Slide 9: Launched the first test on TrueMRD platform in muscle-invasive bladder cancer (MIBC)
Launched the first test on TrueMRD platform in muscle -invasive bladder cancer (MIBC) First and only commercially available Covered by Leverages our truly whole - Medicare strong Decipher for recurrence monitoring genome MRD test in patients with MIBC brand following radical and long -standing relat
Slide 10: Growing Decipher Prostate
Strong increase in new ordering physicians and deeper penetration within Growing Decipher Prostate existing base; orders per 17% physician reached a new record in Q2 Quarterly Volume 29,700 29,700 28,000 26,700 27,250 25,500 22,550 Highest sequential 22,400 21,250 volume growth since Q2 2025 Strong
Slide 11: Decipher Prostate was featured in more than 35 publications and abstracts in Q2
Decipher Prostate was featured in more than 35 publications and abstracts in Q2 Low-risk / active surveillance Intermediate-risk High-risk / advanced disease Investing to generate additional Six oral presentations expected at Level 1B evidence from the high-quality evidence ASTRO including ENZAMET t
Slide 12: Growing Afirma
Increased utilization among existing physicians and continued expansion Growing Afirma of ordering physician base 10% Quarterly Volume 18,250 18,600 18,600 17,200 16,300 16,950 17,000 Improved no-result rate 15,100 15,450 YoY, resulting in ~400 bps of volume growth in Q2 Strengthened evidence base w
Slide 13: Strong topline growth driven by testing revenue
Strong topline growth driven by testing revenue Total Revenue (M)1 Testing Revenue (M)1 Testing Volume (K) Q2 Q2 Q2 $146 $150 $122 48.4 42.4 $130 15% 19% 14% YOY growth YOY growth YOY growth Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Testing ASP of $3,0102 Normalized ASP of $2,9003 +4% YoY +3%
Slide 14: Delivered strong net income and adjusted EBITDA
Delivered strong net income and adjusted EBITDA Cash and Short-term GAAP Net Income (M) Adjusted EBITDA Margin Investments (M)1 Q2 Q2 End of Quarter $485.2 $25.5 29.2% 27.5% $320.7 $(1.0)2 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 1. Ending balance of cash, cash equivalents and short-term inve
Slide 15: Raising revenue outlook for 2026
Raising revenue outlook for 2026 Revenue (M)1 Testing Revenue (M)1 Adjusted EBITDA Margin1,3 $590-$596 $576-$582 $517 $493 14-15% 17-18% YOY growth YOY growth >26% adjusted 2025 2026 2025 2026 EBITDA margin Excludes the contribution of new tests Raised from prior expectations Raised from prior expec
Slide 16: Fueling growth with a steady cadence of expected catalysts
Fueling growth with a steady cadence of expected catalysts 2026 2027+ Afirma Expand Afirma GRID clinical signatures Decipher Expand Decipher clinical signatures TrueMRD Additional TrueMRD indications TrueMRD Launch TrueMRD in MIBC Decipher Launch Decipher OUS Prosigna Launch Prosigna LDT1 Prosigna L
Slide 17: -_ ; ‘W veracyte.
-_ ; ‘W veracyte.
Slide 18: Reconciliation of Non-GAAP Gross Profit and Gross Margin
Reconciliation of Non-GAAP Gross Profit and Gross Margin (Unaudited) (In thousands of dollars) Three Months Ended Mar 31, 2025 Jun 30, 2025 Sep 30, 2025 Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 GAAP cost of testing revenue $ 28,260 $ 32,407 $ 33,777 $ 33,118 $ 33,306 $ 36,309 Stock-based compensation
Slide 19: Reconciliation of Non-GAAP Operating Expenses
Reconciliation of Non-GAAP Operating Expenses (Unaudited) (In thousands of dollars) Three Months Ended Mar 31, 2025 Jun 30, 2025 Sep 30, 2025 Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 GAAP research and development $ 17,720 $ 16,264 $ 15,981 $ 20,849 $ 27,098 $ 29,442 Stock-based compensation expense (2
Slide 20: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA (Unaudited) (In thousands of dollars) Three Months Ended Mar 31, 2025 Jun 30, 2025 Sep 30, 2025 Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 GAAP Net Income (Loss) $ 7,047 $ (980) $ 19,137 $ 41,149 $ 28,707 $ 25,490 GAAP Net Income (Loss) as a % of Revenue 6.2 % (0.8 %) 1
Slide 21: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA (Unaudited) (In thousands of dollars) Twelve Months Ended Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 GAAP Net Income (Loss) $ (75,563) $ (36,560) $ (74,404) $ 24,138 $ 66,353 GAAP Net Income (Loss) as a % of Revenue (34.4 %) (12.3 %) (20.6 %) 5
Slide 22: Reconciliation of Non-GAAP Net Income, EPS and WASO
Reconciliation of Non-GAAP Net Income, EPS and WASO (Unaudited) (In thousands of dollars) Three Months Ended Mar 31, 2025 Jun 30, 2025 Sep 30, 2025 Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 GAAP Net Income (Loss) $ 7,047 $ (980) $ 19,137 $ 41,149 $ 28,707 $ 25,490 Amortization of intangible assets 3,20
Slide 23: Wveracyte.
Wveracyte.